SCHEMBL30242524

SCHEMBL30242524

O=C1NCCCOc2ccc3[nH]nc(c3c2)-c2cccc(c2)CO1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 5/20 0.40
IRAK4 Q9NWZ3 5/20 0.36
IRAK1 P51617 4/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
DYRK1A Q13627 5/20 0.35
MAP2K4 P45985 4/20 0.35
TTK P33981 3/20 0.35
CLK2 P49760 3/20 0.35
CLK3 P49761 2/20 0.35
MAPK1 P28482 2/20 0.34
MAPKAPK3 Q16644 2/20 0.34
MAPK6 Q16659 2/20 0.34
DCLK1 O15075 1/20 0.34
PRKD3 O94806 1/20 0.34
MAP4K4 O95819 1/20 0.34
CHEK2 O96017 1/20 0.34
CSF1R P07333 1/20 0.34
FER P16591 1/20 0.34
CDK2 P24941 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24012463 1.00 GSK3B (0.40) GSK3BIRAK4IRAK1MAPTHPGD
SCHEMBL30242386 0.86 HTR2A (0.33) GSK3BIRAK4IRAK1MAPTHPGD
SCHEMBL30242446 0.86 GSK3B (0.40) GSK3BDYRK1AMAP2K4CLK2CLK3
SCHEMBL24013073 0.86 HTR2A (0.33) GSK3BIRAK4IRAK1MAPTHPGD
SCHEMBL24012561 0.86 GSK3B (0.40) GSK3BDYRK1AMAP2K4CLK2CLK3
SCHEMBL24012451 0.85 NTRK1 (0.33) GSK3BIRAK4IRAK1MAPTHPGD
SCHEMBL30242480 0.85 NTRK1 (0.33) GSK3BIRAK4IRAK1MAPTHPGD
SCHEMBL24012960 0.85 IRAK4 (0.35) GSK3BIRAK4IRAK1MAPTHPGD
SCHEMBL24012694 0.85 MAP2K4 (0.37) GSK3BIRAK4IRAK1MAPTHPGD
SCHEMBL30242421 0.85 IRAK4 (0.35) GSK3BIRAK4IRAK1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545689-B2 Macrocyclic LRRK2 kinase inhibitors ONCODESIGN PRECISION MEDICINE (FR) 2026-02-10 US claimed
EP-4146658-B1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS ONCODESIGN PREC MEDICINE OPM (FR) 2025-10-29 EP claimed
US-20230357269-A1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS ONCODESIGN PRECISION MEDICINE (FR) 2023-11-09 US claimed
EP-4146658-A1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS Les Laboratoires Servier (FR) 2023-03-15 EP claimed
US-12545689-B2 Macrocyclic LRRK2 kinase inhibitors ONCODESIGN PRECISION MEDICINE (FR) 2026-02-10 US disclosed
EP-4146658-B1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS ONCODESIGN PREC MEDICINE OPM (FR) 2025-10-29 EP disclosed
US-20230357269-A1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS ONCODESIGN PRECISION MEDICINE (FR) 2023-11-09 US disclosed
EP-4146658-A1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS Les Laboratoires Servier (FR) 2023-03-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545689-B2 Macrocyclic LRRK2 kinase inhibitors LRRK2, SNCA, ROS1 GSK3B 5/4885IRAK4 1075/4885IRAK1 499/4885
US-20230357269-A1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS LRRK2, RIN1, GRK3 GSK3B 24/4885IRAK4 516/4885IRAK1 265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.